Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Posts Earnings Results, Beats Estimates By $0.31 EPS
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.25 by $0.31, Bloomberg Earnings reports. Alexion Pharmaceuticals had a return on equity of 11.72% and a net margin of 14.52%. The firm had revenue of $912 million for the quarter, compared to analysts’ expectations of $846.15 million. During the same period in the previous year, the firm earned $1.13 EPS. The business’s quarterly revenue was up 21.1% on a year-over-year basis. Alexion Pharmaceuticals updated its FY17 guidance to $5.40-5.55 EPS.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 2.17% during trading on Thursday, hitting $133.92. The stock had a trading volume of 5,111,285 shares. Alexion Pharmaceuticals has a 12 month low of $96.18 and a 12 month high of $145.41. The company’s 50 day moving average is $121.46 and its 200-day moving average is $122.77. The company has a market cap of $30.07 billion, a PE ratio of 63.80 and a beta of 1.39.
In related news, CEO Ludwig Hantson purchased 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The stock was purchased at an average price of $116.72 per share, with a total value of $1,167,200.00. Following the completion of the acquisition, the chief executive officer now owns 38,725 shares in the company, valued at $4,519,982. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 660,779 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The stock was bought at an average cost of $117.33 per share, with a total value of $77,529,200.07. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 2,019,734 shares of company stock valued at $235,606,846. Insiders own 4.35% of the company’s stock.
Large investors have recently bought and sold shares of the company. Hudson Bay Capital Management LP acquired a new stake in Alexion Pharmaceuticals during the fourth quarter valued at about $12,847,000. Morgan Stanley boosted its stake in Alexion Pharmaceuticals by 112.0% in the first quarter. Morgan Stanley now owns 585,482 shares of the biopharmaceutical company’s stock valued at $70,983,000 after buying an additional 309,299 shares during the period. DekaBank Deutsche Girozentrale boosted its stake in Alexion Pharmaceuticals by 18.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 114,493 shares of the biopharmaceutical company’s stock valued at $14,017,000 after buying an additional 17,642 shares during the period. Sumitomo Mitsui Asset Management Company LTD boosted its stake in Alexion Pharmaceuticals by 10.9% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 18,859 shares of the biopharmaceutical company’s stock valued at $2,286,000 after buying an additional 1,849 shares during the period. Finally, Baird Financial Group Inc. boosted its stake in Alexion Pharmaceuticals by 219.0% in the first quarter. Baird Financial Group Inc. now owns 14,606 shares of the biopharmaceutical company’s stock valued at $1,771,000 after buying an additional 10,028 shares during the period. 94.84% of the stock is owned by institutional investors.
ALXN has been the topic of a number of analyst reports. UBS AG initiated coverage on Alexion Pharmaceuticals in a research report on Wednesday, March 29th. They set a “buy” rating and a $138.00 price objective on the stock. Instinet reaffirmed a “buy” rating and set a $148.00 price objective on shares of Alexion Pharmaceuticals in a research report on Thursday, March 30th. Zacks Investment Research raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 18th. Cowen and Company reaffirmed an “outperform” rating and set a $180.00 price objective on shares of Alexion Pharmaceuticals in a research report on Friday, April 28th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $158.00 price objective on shares of Alexion Pharmaceuticals in a research report on Monday, May 1st. Seven analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Alexion Pharmaceuticals has an average rating of “Buy” and an average target price of $156.62.
ILLEGAL ACTIVITY WARNING: This story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/07/27/alexion-pharmaceuticals-inc-nasdaqalxn-posts-earnings-results-beats-estimates-by-0-31-eps.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.